Patents by Inventor Donald G. Blair

Donald G. Blair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for DRM, a secreted protein with cell growth inhibiting activity
    Publication number: 20030078406
    Abstract: The present invention provides an isolated nucleic acid encoding DRM protein, an isolated DRM polypeptide, and a fusion polypeptide comprising a DRM protein and a green fluorescent protein. The present invention also provides a method of arresting the growth of a cell, comprising administering to the cell an effective amount of DRM protein or an active fragment thereof; a method of inhibiting tumor cell growth, comprising administering to a tumor cell an effective amount of DRM protein or an active fragment thereof; and a method of treating a hyperproliferative cell disorder in a subject diagnosed with a hyperproliferative cell disorder, comprising administering to the subject an effective amount of DRM protein or an active fragment thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 27, 2001
    Publication date: April 24, 2003
    Applicant: The Government of the U.S.A., as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Donald G. Blair, Peter A. Clausen, Lilia Z. Topol, Maria Marx, Georges Calothy
  • ETS2 repressor factor (ERF)
    Patent number: 6194547
    Abstract: The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: February 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George J. Mavrothalassitis, Donald G. Blair, Robert J. Fisher, Gregory J. Beal, Jr., Meropi A. Athanasiou, Dionyssios N. Sgouras
  • ETS2 repressor factor (ERF) genetic locus and its products
    Patent number: 5856125
    Abstract: The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 5, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George J. Mavrothalassitis, Donald G. Blair, Robert J. Fisher, Gregory J. Beal, Jr., Meropi A. Athanasiou, Dionyssios N. Sgouras
  • Method of treating retroviral infections in mammals
    Patent number: 5622959
    Abstract: The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: April 22, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Esther Priel, Donald G. Blair, Stephen D. Showalter
  • Method of treating retroviral infections in mammals
    Patent number: 5422344
    Abstract: The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.
    Type: Grant
    Filed: May 8, 1990
    Date of Patent: June 6, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Esther Priel, Donald G. Blair, Stephen D. Showalter
  • LTR-Vectors
    Patent number: 4405712
    Abstract: The production of vectors composed of portions of retrovirus, particularly of Moloney sarcoma virus DNA including the "LTR" sequence which can activate genes and additional viral sequences which can "rescue" these genes into a replicating virus particle.
    Type: Grant
    Filed: July 1, 1981
    Date of Patent: September 20, 1983
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George F. Vande Woude, William L. McClements, Marianne K. Oskarsson, Donald G. Blair